Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

Aster DM Healthcare launches Pediatric & Geriatric Emergency Departments at Aster MIMS, Calicut

Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings

Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy

Concerted efforts of individual and institutions needed for organ donation and transplantation: MoS Health Anupriya Patel

Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs

HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.

Bayer submits NDA to USFDA for elinzanetant for the treatment of VMS associated with menopause

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo